Guided Therapeutics Stock Buy Hold or Sell Recommendation
| GTHP Stock | USD 0.19 0.03 18.75% |
Given the investment horizon of 90 days and your below-average risk tolerance, our recommendation regarding Guided Therapeutics is 'Strong Sell'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Guided Therapeutics given historical horizon and risk tolerance towards Guided Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for Guided Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Guided Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Guided and provide practical buy, sell, or hold advice based on investors' constraints. Guided Therapeutics. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in rate.
Guided |
Execute Guided Therapeutics Buy or Sell Advice
The Guided recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Guided Therapeutics. Macroaxis does not own or have any residual interests in Guided Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Guided Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | OK | Details | |
Volatility | Out of control | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Moves totally opposite to the market | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Guided Therapeutics Trading Alerts and Improvement Suggestions
| Guided Therapeutics is way too risky over 90 days horizon | |
| Guided Therapeutics has some characteristics of a very speculative penny stock | |
| Guided Therapeutics appears to be risky and price may revert if volatility continues | |
| Guided Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Guided Therapeutics currently holds 1.43 M in liabilities with Debt to Equity (D/E) ratio of 0.6, which is about average as compared to similar companies. Guided Therapeutics has a current ratio of 0.18, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Guided Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Guided Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Guided Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Guided to invest in growth at high rates of return. When we think about Guided Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 81 K. Net Loss for the year was (2.07 M) with profit before overhead, payroll, taxes, and interest of 20 K. | |
| Guided Therapeutics currently holds about 446 K in cash with (1.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 40.0% of Guided Therapeutics shares are held by company insiders |
Guided Therapeutics Returns Distribution Density
The distribution of Guided Therapeutics' historical returns is an attempt to chart the uncertainty of Guided Therapeutics' future price movements. The chart of the probability distribution of Guided Therapeutics daily returns describes the distribution of returns around its average expected value. We use Guided Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Guided Therapeutics returns is essential to provide solid investment advice for Guided Therapeutics.
| Mean Return | 1.92 | Value At Risk | -20 | Potential Upside | 26.67 | Standard Deviation | 15.76 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Guided Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Guided Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Guided Therapeutics or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Guided Therapeutics' price will be affected by overall otc stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Guided otc's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 2.03 | |
β | Beta against Dow Jones | -0.95 | |
σ | Overall volatility | 15.70 | |
Ir | Information ratio | 0.11 |
Guided Therapeutics Volatility Alert
Guided Therapeutics is showing large volatility of returns over the selected time horizon. Guided Therapeutics is a potential penny stock. Although Guided Therapeutics may be in fact a good instrument to invest, many penny otc stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Guided Therapeutics. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Guided instrument if you perfectly time your entry and exit. However, remember that penny otcs that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Guided Therapeutics Fundamentals Vs Peers
Comparing Guided Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Guided Therapeutics' direct or indirect competition across all of the common fundamentals between Guided Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Guided Therapeutics or determine the otc stocks which would be an excellent addition to an existing portfolio. Peer analysis of Guided Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Guided Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Guided Therapeutics to competition |
| Fundamentals | Guided Therapeutics | Peer Average |
| Return On Asset | -0.63 | -0.14 |
| Operating Margin | (38.63) % | (5.51) % |
| Current Valuation | 19.66 M | 16.62 B |
| Shares Outstanding | 48.58 M | 571.82 M |
| Shares Owned By Insiders | 39.69 % | 10.09 % |
| Shares Owned By Institutions | 12.65 % | 39.21 % |
| Price To Earning | 36.67 X | 28.72 X |
| Price To Sales | 219.47 X | 11.42 X |
| Revenue | 81 K | 9.43 B |
| Gross Profit | 20 K | 27.38 B |
| EBITDA | (837 K) | 3.9 B |
| Net Income | (2.07 M) | 570.98 M |
| Cash And Equivalents | 446 K | 2.7 B |
| Cash Per Share | 0.01 X | 5.01 X |
| Total Debt | 1.43 M | 5.32 B |
| Debt To Equity | 0.60 % | 48.70 % |
| Current Ratio | 0.18 X | 2.16 X |
| Book Value Per Share | (0.13) X | 1.93 K |
| Cash Flow From Operations | (1.59 M) | 971.22 M |
| Earnings Per Share | (0.19) X | 3.12 X |
| Number Of Employees | 5 | 18.84 K |
| Beta | 0.67 | -0.15 |
| Market Capitalization | 12.77 M | 19.03 B |
| Total Asset | 2.04 M | 29.47 B |
| Retained Earnings | (125.47 M) | 9.33 B |
| Working Capital | (6.68 M) | 1.48 B |
| Current Asset | 1.86 M | 9.34 B |
| Current Liabilities | 8.55 M | 7.9 B |
| Z Score | -84.2 | 8.72 |
| Net Asset | 2.04 M |
Guided Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Guided . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Daily Balance Of Power | 9.2 T | |||
| Rate Of Daily Change | 1.19 | |||
| Day Median Price | 0.19 | |||
| Day Typical Price | 0.19 | |||
| Price Action Indicator | 0.015 | |||
| Period Momentum Indicator | 0.03 | |||
| Relative Strength Index | 56.87 |
About Guided Therapeutics Buy or Sell Advice
When is the right time to buy or sell Guided Therapeutics? Buying financial instruments such as Guided OTC Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Guided Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Recreation Thematic Idea Now
Recreation
Companies involved in production and services of recreational goods, foods, and accessories. The Recreation theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Recreation Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Guided OTC Stock Analysis
When running Guided Therapeutics' price analysis, check to measure Guided Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Guided Therapeutics is operating at the current time. Most of Guided Therapeutics' value examination focuses on studying past and present price action to predict the probability of Guided Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Guided Therapeutics' price. Additionally, you may evaluate how the addition of Guided Therapeutics to your portfolios can decrease your overall portfolio volatility.